| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clinical Laboratory Techniques | 4 | 2021 | 76 | 1.090 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2019 | 150 | 0.790 |
Why?
|
| Antibodies, Viral | 2 | 2020 | 311 | 0.780 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2021 | 282 | 0.780 |
Why?
|
| Microbiological Techniques | 2 | 2017 | 24 | 0.710 |
Why?
|
| Blood | 2 | 2017 | 69 | 0.710 |
Why?
|
| Betacoronavirus | 2 | 2020 | 262 | 0.700 |
Why?
|
| Immunoglobulin A | 1 | 2020 | 83 | 0.690 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 373 | 0.650 |
Why?
|
| Immunoglobulin G | 2 | 2020 | 469 | 0.640 |
Why?
|
| Bacteria | 4 | 2017 | 481 | 0.630 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 319 | 0.610 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 305 | 0.610 |
Why?
|
| Fungi | 1 | 2017 | 66 | 0.580 |
Why?
|
| Workflow | 1 | 2017 | 81 | 0.570 |
Why?
|
| Molecular Diagnostic Techniques | 4 | 2020 | 72 | 0.550 |
Why?
|
| Sensitivity and Specificity | 11 | 2024 | 2016 | 0.480 |
Why?
|
| Refugees | 1 | 2014 | 6 | 0.460 |
Why?
|
| Social Adjustment | 1 | 2014 | 47 | 0.460 |
Why?
|
| Sepsis | 1 | 2017 | 326 | 0.450 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 43 | 0.440 |
Why?
|
| Graphite | 2 | 2023 | 12 | 0.420 |
Why?
|
| Staphylococcal Infections | 4 | 2019 | 271 | 0.400 |
Why?
|
| Bacteriological Techniques | 4 | 2019 | 39 | 0.350 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 435 | 0.330 |
Why?
|
| Specimen Handling | 3 | 2021 | 103 | 0.320 |
Why?
|
| Nasopharynx | 5 | 2021 | 50 | 0.320 |
Why?
|
| Influenza, Human | 3 | 2017 | 340 | 0.320 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2021 | 27 | 0.310 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2020 | 40 | 0.300 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2014 | 78 | 0.300 |
Why?
|
| Anti-Bacterial Agents | 5 | 2023 | 795 | 0.290 |
Why?
|
| Bacteremia | 4 | 2014 | 102 | 0.290 |
Why?
|
| HIV-1 | 2 | 2022 | 167 | 0.290 |
Why?
|
| Humans | 51 | 2024 | 89613 | 0.280 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2017 | 25 | 0.280 |
Why?
|
| HIV Infections | 4 | 2022 | 846 | 0.270 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2021 | 195 | 0.270 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 106 | 0.270 |
Why?
|
| Hospitals, University | 3 | 2017 | 196 | 0.270 |
Why?
|
| Reagent Kits, Diagnostic | 4 | 2021 | 38 | 0.250 |
Why?
|
| Automation, Laboratory | 2 | 2017 | 12 | 0.250 |
Why?
|
| DNA, Bacterial | 5 | 2019 | 244 | 0.240 |
Why?
|
| Legionellosis | 1 | 2024 | 6 | 0.240 |
Why?
|
| Legionella | 1 | 2024 | 16 | 0.240 |
Why?
|
| Endocarditis, Bacterial | 1 | 2024 | 39 | 0.240 |
Why?
|
| Toxoplasmosis, Congenital | 1 | 2024 | 49 | 0.230 |
Why?
|
| Saliva | 2 | 2023 | 124 | 0.230 |
Why?
|
| Carrier State | 2 | 2015 | 39 | 0.230 |
Why?
|
| Lactulose | 1 | 2023 | 22 | 0.220 |
Why?
|
| Hepatic Encephalopathy | 1 | 2023 | 39 | 0.220 |
Why?
|
| RNA, Viral | 2 | 2021 | 318 | 0.220 |
Why?
|
| Mycobacterium | 2 | 2000 | 18 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2021 | 885 | 0.200 |
Why?
|
| Point-of-Care Systems | 2 | 2021 | 145 | 0.190 |
Why?
|
| Chicago | 4 | 2020 | 1430 | 0.190 |
Why?
|
| Mycobacterium chelonae | 1 | 2021 | 4 | 0.190 |
Why?
|
| Biosensing Techniques | 1 | 2022 | 73 | 0.190 |
Why?
|
| Aspergillosis | 2 | 1992 | 41 | 0.190 |
Why?
|
| Time Factors | 7 | 2021 | 5337 | 0.190 |
Why?
|
| Mycobacterium Infections | 1 | 2000 | 15 | 0.180 |
Why?
|
| Symptom Assessment | 1 | 2020 | 66 | 0.180 |
Why?
|
| Serologic Tests | 1 | 2020 | 43 | 0.180 |
Why?
|
| Antibody Formation | 1 | 2020 | 171 | 0.170 |
Why?
|
| Immunocompromised Host | 3 | 2021 | 142 | 0.170 |
Why?
|
| Yersinia pseudotuberculosis Infections | 1 | 1999 | 2 | 0.170 |
Why?
|
| Food Microbiology | 1 | 1999 | 9 | 0.170 |
Why?
|
| Yersinia pseudotuberculosis | 1 | 1999 | 6 | 0.170 |
Why?
|
| Influenza B virus | 2 | 2017 | 32 | 0.170 |
Why?
|
| Nasal Mucosa | 1 | 2020 | 191 | 0.170 |
Why?
|
| Endophthalmitis | 1 | 2019 | 22 | 0.170 |
Why?
|
| Multiplex Polymerase Chain Reaction | 2 | 2018 | 35 | 0.170 |
Why?
|
| Yersinia enterocolitica | 1 | 1999 | 18 | 0.170 |
Why?
|
| Pharyngitis | 1 | 2019 | 15 | 0.170 |
Why?
|
| Streptococcus pyogenes | 1 | 2019 | 35 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 919 | 0.160 |
Why?
|
| Community-Acquired Infections | 3 | 2014 | 65 | 0.160 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 56 | 0.160 |
Why?
|
| Bordetella Infections | 1 | 2018 | 5 | 0.160 |
Why?
|
| Pharynx | 2 | 2019 | 44 | 0.160 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2019 | 76 | 0.160 |
Why?
|
| Influenza A virus | 2 | 2017 | 172 | 0.160 |
Why?
|
| Sputum | 2 | 2015 | 35 | 0.160 |
Why?
|
| Clostridium Infections | 1 | 2020 | 125 | 0.150 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 23 | 0.150 |
Why?
|
| Drug Utilization | 1 | 2018 | 66 | 0.150 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 160 | 0.150 |
Why?
|
| Disease Outbreaks | 2 | 2015 | 156 | 0.140 |
Why?
|
| Pandemics | 2 | 2020 | 777 | 0.140 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 91 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 352 | 0.140 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 276 | 0.140 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2016 | 17 | 0.130 |
Why?
|
| Enterovirus D, Human | 1 | 2015 | 4 | 0.130 |
Why?
|
| Male | 19 | 2021 | 42488 | 0.130 |
Why?
|
| United States | 6 | 2021 | 7050 | 0.130 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2015 | 10 | 0.120 |
Why?
|
| Water Microbiology | 1 | 2015 | 13 | 0.120 |
Why?
|
| Nose | 2 | 2013 | 94 | 0.120 |
Why?
|
| Female | 19 | 2024 | 46401 | 0.120 |
Why?
|
| Torture | 1 | 2014 | 2 | 0.120 |
Why?
|
| Adoption | 1 | 2014 | 9 | 0.120 |
Why?
|
| Patient Isolation | 1 | 2014 | 14 | 0.120 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 2763 | 0.110 |
Why?
|
| Nasal Cavity | 1 | 2014 | 91 | 0.110 |
Why?
|
| Tuberculosis | 1 | 1995 | 121 | 0.110 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 150 | 0.110 |
Why?
|
| Child | 5 | 2017 | 7216 | 0.110 |
Why?
|
| Prisons | 1 | 2013 | 12 | 0.110 |
Why?
|
| Health Personnel | 1 | 2015 | 214 | 0.100 |
Why?
|
| Brain Abscess | 1 | 1992 | 8 | 0.100 |
Why?
|
| Pelvic Neoplasms | 1 | 1992 | 44 | 0.100 |
Why?
|
| Aspergillus fumigatus | 1 | 1992 | 18 | 0.100 |
Why?
|
| HIV | 1 | 2012 | 48 | 0.100 |
Why?
|
| Adult | 13 | 2021 | 26704 | 0.100 |
Why?
|
| Laboratories | 2 | 2010 | 44 | 0.100 |
Why?
|
| Ascomycota | 1 | 2011 | 16 | 0.100 |
Why?
|
| False Positive Reactions | 2 | 2024 | 223 | 0.100 |
Why?
|
| Bacterial Typing Techniques | 1 | 2011 | 28 | 0.090 |
Why?
|
| AIDS Serodiagnosis | 1 | 2011 | 26 | 0.090 |
Why?
|
| Sarcoma | 2 | 1992 | 219 | 0.090 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1991 | 25 | 0.090 |
Why?
|
| Mycoses | 1 | 2011 | 46 | 0.090 |
Why?
|
| Lung Diseases, Fungal | 1 | 1991 | 18 | 0.090 |
Why?
|
| Disease Notification | 1 | 2010 | 4 | 0.090 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2011 | 64 | 0.090 |
Why?
|
| Skin | 1 | 2014 | 589 | 0.090 |
Why?
|
| Bioterrorism | 1 | 2010 | 18 | 0.090 |
Why?
|
| Heart Neoplasms | 1 | 1991 | 63 | 0.090 |
Why?
|
| Cysts | 1 | 2011 | 106 | 0.090 |
Why?
|
| Diarrhea | 1 | 1991 | 178 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1991 | 174 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1991 | 152 | 0.080 |
Why?
|
| Feces | 1 | 1991 | 331 | 0.080 |
Why?
|
| Sexual Behavior | 1 | 2012 | 312 | 0.080 |
Why?
|
| Middle Aged | 10 | 2021 | 26012 | 0.080 |
Why?
|
| Heart Atria | 1 | 1991 | 282 | 0.080 |
Why?
|
| Homosexuality, Male | 1 | 2012 | 302 | 0.080 |
Why?
|
| Aged | 9 | 2020 | 19158 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 524 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 1991 | 523 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2017 | 3756 | 0.060 |
Why?
|
| Antibodies, Protozoan | 1 | 2024 | 42 | 0.060 |
Why?
|
| Bacterial Infections | 2 | 2010 | 184 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2024 | 296 | 0.060 |
Why?
|
| Immunoglobulin M | 1 | 2024 | 163 | 0.060 |
Why?
|
| Prenatal Diagnosis | 1 | 2024 | 110 | 0.060 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2014 | 20 | 0.060 |
Why?
|
| Toxoplasma | 1 | 2024 | 116 | 0.050 |
Why?
|
| Adolescent | 5 | 2017 | 9305 | 0.050 |
Why?
|
| HIV Antigens | 1 | 2022 | 4 | 0.050 |
Why?
|
| HIV-2 | 1 | 2022 | 4 | 0.050 |
Why?
|
| Young Adult | 4 | 2017 | 6368 | 0.050 |
Why?
|
| HIV Antibodies | 1 | 2022 | 26 | 0.050 |
Why?
|
| Immunoassay | 1 | 2022 | 91 | 0.050 |
Why?
|
| Transistors, Electronic | 1 | 2022 | 4 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 44 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 3 | 1997 | 270 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2020 | 71 | 0.050 |
Why?
|
| Viral Load | 1 | 2021 | 145 | 0.050 |
Why?
|
| Lung Transplantation | 1 | 2024 | 293 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2012 | 590 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 2000 | 53 | 0.040 |
Why?
|
| Infant | 2 | 2017 | 3176 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 48 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 123 | 0.040 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2000 | 41 | 0.040 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2000 | 58 | 0.040 |
Why?
|
| Vitreous Body | 1 | 2019 | 54 | 0.040 |
Why?
|
| History, 19th Century | 1 | 1999 | 56 | 0.040 |
Why?
|
| Biopsy | 2 | 2021 | 1183 | 0.040 |
Why?
|
| Australia | 1 | 1999 | 101 | 0.040 |
Why?
|
| Point-of-Care Testing | 1 | 2019 | 24 | 0.040 |
Why?
|
| North America | 1 | 1999 | 184 | 0.040 |
Why?
|
| Bordetella bronchiseptica | 1 | 2018 | 6 | 0.040 |
Why?
|
| Bordetella pertussis | 1 | 2018 | 15 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2018 | 109 | 0.040 |
Why?
|
| Europe | 1 | 1999 | 322 | 0.040 |
Why?
|
| Antigens, Bacterial | 1 | 2019 | 136 | 0.040 |
Why?
|
| Virulence | 1 | 1999 | 281 | 0.040 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2018 | 13 | 0.040 |
Why?
|
| Pregnancy | 2 | 2024 | 3038 | 0.040 |
Why?
|
| Medical Audit | 1 | 2018 | 39 | 0.040 |
Why?
|
| Prevalence | 2 | 2013 | 1247 | 0.040 |
Why?
|
| Swine | 1 | 2019 | 588 | 0.040 |
Why?
|
| History, 20th Century | 1 | 1999 | 312 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2024 | 2488 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 6771 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 384 | 0.040 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2017 | 8 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 110 | 0.040 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 102 | 0.040 |
Why?
|
| Inpatients | 1 | 2020 | 311 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 782 | 0.040 |
Why?
|
| Animals | 3 | 2023 | 27481 | 0.040 |
Why?
|
| Virology | 1 | 1996 | 9 | 0.030 |
Why?
|
| Phenotype | 2 | 2014 | 2449 | 0.030 |
Why?
|
| Chlamydia trachomatis | 2 | 2011 | 15 | 0.030 |
Why?
|
| Rhinovirus | 1 | 2015 | 25 | 0.030 |
Why?
|
| Neisseria gonorrhoeae | 2 | 2011 | 17 | 0.030 |
Why?
|
| Case Management | 1 | 1995 | 25 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 1995 | 46 | 0.030 |
Why?
|
| Bacteria, Aerobic | 1 | 1995 | 1 | 0.030 |
Why?
|
| Anesthesia, Local | 1 | 1995 | 27 | 0.030 |
Why?
|
| Gastric Juice | 1 | 2015 | 15 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2015 | 46 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1995 | 168 | 0.030 |
Why?
|
| Lidocaine | 1 | 1995 | 65 | 0.030 |
Why?
|
| Osteomyelitis | 1 | 1995 | 55 | 0.030 |
Why?
|
| Chorionic Villi Sampling | 1 | 1994 | 13 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2015 | 127 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 1995 | 250 | 0.030 |
Why?
|
| Risk Factors | 3 | 2013 | 5517 | 0.030 |
Why?
|
| Drinking Water | 1 | 2015 | 64 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1727 | 0.030 |
Why?
|
| Viruses | 1 | 2015 | 78 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 4 | 1991 | 2668 | 0.030 |
Why?
|
| Bone and Bones | 1 | 1995 | 271 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 476 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2013 | 19 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 170 | 0.030 |
Why?
|
| Temperature | 1 | 2014 | 407 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2384 | 0.030 |
Why?
|
| Burkitt Lymphoma | 1 | 1992 | 32 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2012 | 32 | 0.020 |
Why?
|
| Paraganglioma | 1 | 1991 | 16 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2012 | 52 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2017 | 4309 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2011 | 130 | 0.020 |
Why?
|
| Soft Tissue Infections | 1 | 2011 | 26 | 0.020 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 51 | 0.020 |
Why?
|
| Headache | 1 | 1991 | 73 | 0.020 |
Why?
|
| Microscopy | 1 | 2011 | 87 | 0.020 |
Why?
|
| Cervix Uteri | 1 | 2011 | 71 | 0.020 |
Why?
|
| Femur | 1 | 1991 | 112 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2020 | 8218 | 0.020 |
Why?
|
| Urine | 1 | 2011 | 92 | 0.020 |
Why?
|
| Francisella tularensis | 1 | 2010 | 9 | 0.020 |
Why?
|
| Brucella abortus | 1 | 2010 | 12 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 23 | 0.020 |
Why?
|
| Civil Defense | 1 | 2010 | 11 | 0.020 |
Why?
|
| Pathology | 1 | 2010 | 32 | 0.020 |
Why?
|
| Leukemia, Myeloid | 1 | 1991 | 249 | 0.020 |
Why?
|
| Illinois | 1 | 2012 | 484 | 0.020 |
Why?
|
| Urethra | 1 | 2011 | 116 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 984 | 0.020 |
Why?
|
| Bacillus anthracis | 1 | 2010 | 73 | 0.020 |
Why?
|
| Counseling | 1 | 2011 | 166 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 11832 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2011 | 172 | 0.020 |
Why?
|
| Public Health | 1 | 2010 | 140 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1991 | 322 | 0.020 |
Why?
|
| Radiography | 1 | 1991 | 806 | 0.020 |
Why?
|
| Informed Consent | 1 | 2011 | 275 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1991 | 714 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2014 | 898 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1992 | 395 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1992 | 1605 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1991 | 366 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 1853 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 1877 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 1991 | 976 | 0.020 |
Why?
|
| Hypertension | 1 | 1991 | 747 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1991 | 1353 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2018 | 9127 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2000 | 3659 | 0.010 |
Why?
|
| Philadelphia | 1 | 2000 | 18 | 0.010 |
Why?
|
| Equipment Contamination | 1 | 1997 | 23 | 0.010 |
Why?
|
| Automation | 1 | 1996 | 111 | 0.010 |
Why?
|
| Hepacivirus | 1 | 1996 | 131 | 0.010 |
Why?
|
| Incidence | 1 | 2000 | 1598 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1995 | 63 | 0.010 |
Why?
|
| Registries | 1 | 2000 | 791 | 0.010 |
Why?
|
| Knee | 1 | 1991 | 17 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1991 | 222 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1995 | 2884 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 1991 | 3465 | 0.010 |
Why?
|